SeaStar Medical Holding (ICU)
NASDAQ:ICU
ICU Stock Chart & Stats
$2.30
-$0.08(-3.90%)
At close: 4:00 PM EST
$2.30
-$0.08(-3.90%)
Day’s Range― - ―
52-Week Range$2.07 - $19.06
Previous CloseN/A
Volume52.61K
Average Volume (3M)3.06M
Market Cap
$10.94M
Enterprise Value-$3.81M
Total Cash (Recent Filing)$11.98M
Total Debt (Recent Filing)$525.00K
Price to Earnings (P/E)―
Beta1.19
Next Earnings
May 19, 2026EPS Estimate
-0.92Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.80
Shares Outstanding3,993,719
10 Day Avg. Volume1,756,841
30 Day Avg. Volume3,057,972
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)4.78
Price to Sales (P/S)40.32
P/FCF Ratio-3.66
Enterprise Value/Market Cap-0.35
Enterprise Value/Revenue-3.09
Enterprise Value/Gross Profit-3.23
Enterprise Value/Ebitda0.31
Forecast
1Y Price Target
$6.00Price Target Upside160.87% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-3.33
Revenue Forecast (FY)$1.87M
Bulls Say, Bears Say
Bulls Say
Clinical And Regulatory ProgressAnalyst points to the NEUTRALIZE-AKI trial passing its enrollment midpoint and completion of regulatory submission components not contingent on trial outcomes, which could accelerate FDA review and shorten the path to market if clinical results are favorable.
Financial ResultsAnalyst notes the company reported quarterly results that exceeded expectations for revenue, gross margin, and GAAP loss per share, signaling improving financial performance and operational leverage.
Pediatric Commercial ExpansionAnalyst highlights expansion of QUELIMMUNE adoption at children's hospitals and a pipeline of additional hospitals, supporting growing commercial traction in the pediatric market.
Bears Say
Cash Runway And Financing RiskAnalyst warns that current cash levels combined with ongoing cash burn imply the company will need to raise additional capital, introducing execution risk for development and commercialization plans.
Potential Delays From Financing UncertaintyAnalyst notes that the need to secure additional financing creates uncertainty that could delay development programs and planned commercialization initiatives, increasing milestone risk.
Share Dilution And Valuation PressureAnalyst indicates an expected capital raise would cause share dilution and exert downward pressure on per‑share value, prompting a lowered price target.
SeaStar Medical Holding News
ICU FAQ
What was SeaStar Medical Holding’s price range in the past 12 months?
SeaStar Medical Holding lowest stock price was $2.07 and its highest was $19.06 in the past 12 months.
What is SeaStar Medical Holding’s market cap?
SeaStar Medical Holding’s market cap is $10.94M.
When is SeaStar Medical Holding’s upcoming earnings report date?
SeaStar Medical Holding’s upcoming earnings report date is May 19, 2026 which is in 50 days.
How were SeaStar Medical Holding’s earnings last quarter?
SeaStar Medical Holding released its earnings results on Mar 25, 2026. The company reported -$0.8 earnings per share for the quarter, beating the consensus estimate of -$1.08 by $0.28.
Is SeaStar Medical Holding overvalued?
According to Wall Street analysts SeaStar Medical Holding’s price is currently Undervalued.
Does SeaStar Medical Holding pay dividends?
SeaStar Medical Holding does not currently pay dividends.
What is SeaStar Medical Holding’s EPS estimate?
SeaStar Medical Holding’s EPS estimate is -0.92.
How many shares outstanding does SeaStar Medical Holding have?
SeaStar Medical Holding has 3,993,719 shares outstanding.
What happened to SeaStar Medical Holding’s price movement after its last earnings report?
SeaStar Medical Holding reported an EPS of -$0.8 in its last earnings report, beating expectations of -$1.08. Following the earnings report the stock price went up 22.368%.
Which hedge fund is a major shareholder of SeaStar Medical Holding?
Currently, no hedge funds are holding shares in ICU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SeaStar Medical Holding
SeaStar Medical Holding Corporation, a medical device company, focuses on providing novel solutions and services to treat hyperinflammation and cytokine storm in critically ill patients. The company is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. It is developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure with and without LVAD; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is based in Denver, Colorado.
ICU Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call showcased several positive developments, including impressive survival results from Quellimmune therapy, significant revenue growth, and a high gross profit margin. The expansion of clinical sites and a strengthened financial position further underline the company's potential. However, the variability in sales and the increased enrollment requirement for the pivotal trial pose challenges. Despite these, the overall sentiment is positive with a strategic focus on overcoming hurdles and continuing growth.View all ICU earnings summariesICU Stock 12 Month Forecast
Average Price Target
$6.00
▲(160.87% Upside)
Technical Analysis
Ownership Overview
3.38% Insiders
<0.01% Other Institutional Investors
95.99% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---